Literature DB >> 10725303

Human cytochrome P450 maximal activities in pediatric versus adult liver.

J G Blanco1, P L Harrison, W E Evans, M V Relling.   

Abstract

Drug clearance is often higher in children than in adults, particularly when normalized to body weight. We previously showed that liver volume normalized to body weight was inversely related to age, but that the systemic clearance of a nonspecific cytochrome P450 (CYP) substrate (antipyrine) was higher in young children compared with adults even when normalized per liver volume. Our purpose herein was to evaluate whether P450 catalytic activities, expressed as maximal catalytic rates per milligram of microsomal protein, differed in up to 37 normal livers from subjects <10 (range 0.5-9 years of age), >10 but <60 years of age (range 10-59 years), and >60 year (range 63-93 years of age). There were no age-related differences in the oxidation of ethoxyresorufin (P =.83) (CYP1A2), ethoxycoumarin (P =.52) (CYP2E1 and other P450s), teniposide (P =. 58), midazolam (P =.47) (CYP3A4/3A5), or paclitaxel (P =.24) (at the 17alpha position, CYP2C8). Tolbutamide hydroxylation tended to be lower in children versus adults (P =.047) (CYP2C9), but did not reach statistical significance after correcting for multiple comparisons. No relationship was found to exist between age and microsomal recovery (P =.98); thus, recovery did not account for the lack of age-related differences in catalytic activity. We conclude that increased intrinsic cytochrome P450 activity is unlikely to account for increased clearance of most P450 drug substrates in children.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10725303

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  21 in total

Review 1.  The Pediatric Cell Atlas: Defining the Growth Phase of Human Development at Single-Cell Resolution.

Authors:  Deanne M Taylor; Bruce J Aronow; Kai Tan; Kathrin Bernt; Nathan Salomonis; Casey S Greene; Alina Frolova; Sarah E Henrickson; Andrew Wells; Liming Pei; Jyoti K Jaiswal; Jeffrey Whitsett; Kathryn E Hamilton; Sonya A MacParland; Judith Kelsen; Robert O Heuckeroth; S Steven Potter; Laura A Vella; Natalie A Terry; Louis R Ghanem; Benjamin C Kennedy; Ingo Helbig; Kathleen E Sullivan; Leslie Castelo-Soccio; Arnold Kreigstein; Florian Herse; Martijn C Nawijn; Gerard H Koppelman; Melissa Haendel; Nomi L Harris; Jo Lynne Rokita; Yuanchao Zhang; Aviv Regev; Orit Rozenblatt-Rosen; Jennifer E Rood; Timothy L Tickle; Roser Vento-Tormo; Saif Alimohamed; Monkol Lek; Jessica C Mar; Kathleen M Loomes; David M Barrett; Prech Uapinyoying; Alan H Beggs; Pankaj B Agrawal; Yi-Wen Chen; Amanda B Muir; Lana X Garmire; Scott B Snapper; Javad Nazarian; Steven H Seeholzer; Hossein Fazelinia; Larry N Singh; Robert B Faryabi; Pichai Raman; Noor Dawany; Hongbo Michael Xie; Batsal Devkota; Sharon J Diskin; Stewart A Anderson; Eric F Rappaport; William Peranteau; Kathryn A Wikenheiser-Brokamp; Sarah Teichmann; Douglas Wallace; Tao Peng; Yang-Yang Ding; Man S Kim; Yi Xing; Sek Won Kong; Carsten G Bönnemann; Kenneth D Mandl; Peter S White
Journal:  Dev Cell       Date:  2019-03-28       Impact factor: 12.270

2.  Reduced Exposure to Piperaquine, Compared to Adults, in Young Children Receiving Dihydroartemisinin-Piperaquine as Malaria Chemoprevention.

Authors:  Meghan E Whalen; Richard Kajubi; Nona Chamankhah; Liusheng Huang; Francis Orukan; Erika Wallender; Moses R Kamya; Grant Dorsey; Prasanna Jagannathan; Philip J Rosenthal; Norah Mwebaza; Francesca T Aweeka
Journal:  Clin Pharmacol Ther       Date:  2019-07-22       Impact factor: 6.875

3.  A mechanistic approach for the scaling of clearance in children.

Authors:  Andrea N Edginton; Walter Schmitt; Barbara Voith; Stefan Willmann
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

4.  Prediction of drug clearance in children: an evaluation of the predictive performance of several models.

Authors:  Iftekhar Mahmood; Carl-Michael Staschen; Kosalaram Goteti
Journal:  AAPS J       Date:  2014-10-02       Impact factor: 4.009

Review 5.  Review: Pharmacogenetic aspects of the effect of cytochrome P450 polymorphisms on serotonergic drug metabolism, response, interactions, and adverse effects.

Authors:  J L Pilgrim; D Gerostamoulos; Olaf H Drummer
Journal:  Forensic Sci Med Pathol       Date:  2010-11-04       Impact factor: 2.007

Review 6.  Guidelines on paediatric dosing on the basis of developmental physiology and pharmacokinetic considerations.

Authors:  Imke H Bartelink; Carin M A Rademaker; Alfred F A M Schobben; John N van den Anker
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

7.  In vitro Phase I- and Phase II-Drug Metabolism in The Liver of Juvenile and Adult Göttingen Minipigs.

Authors:  Els Van Peer; Frank Jacobs; Jan Snoeys; Jos Van Houdt; Ils Pijpers; Christophe Casteleyn; Chris Van Ginneken; Steven Van Cruchten
Journal:  Pharm Res       Date:  2017-01-17       Impact factor: 4.200

Review 8.  Liver 'organ on a chip'.

Authors:  Colin H Beckwitt; Amanda M Clark; Sarah Wheeler; D Lansing Taylor; Donna B Stolz; Linda Griffith; Alan Wells
Journal:  Exp Cell Res       Date:  2017-12-29       Impact factor: 3.905

Review 9.  Clinical use and pharmacological properties of selective COX-2 inhibitors.

Authors:  Shaojun Shi; Ulrich Klotz
Journal:  Eur J Clin Pharmacol       Date:  2007-11-13       Impact factor: 2.953

10.  Drug-induced liver graft toxicity caused by cytochrome P450 poor metabolism.

Authors:  László Kóbori; Krisztina Kõhalmy; Pálma Porrogi; Enikõ Sárváry; Zsuzsa Gerlei; János Fazakas; Péter Nagy; Jenõ Járay; Katalin Monostory
Journal:  Br J Clin Pharmacol       Date:  2007-12-07       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.